Sputum eosinophilia is a useful biomarker for treatment failure of biologics for severe eosinophilic asthma
T. Smidt-Hansen (Aarhus, Denmark), H. Andersen (Aarhus, Denmark), L. Pedersen (Aarhus, Denmark), A. Bjerrum (Aarhus, Denmark), T. Skjold (Aarhus, Denmark), R. Poulsen (Aarhus, Denmark), S. Petersen (Aarhus, Denmark), H. Hoffmann (Aarhus, Denmark), J. Schmid (Aarhus, Denmark)
Source: International Congress 2022 – Severe asthma: from phenotypes to exacerbations
Session: Severe asthma: from phenotypes to exacerbations
Session type: Thematic Poster
Number: 880
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Smidt-Hansen (Aarhus, Denmark), H. Andersen (Aarhus, Denmark), L. Pedersen (Aarhus, Denmark), A. Bjerrum (Aarhus, Denmark), T. Skjold (Aarhus, Denmark), R. Poulsen (Aarhus, Denmark), S. Petersen (Aarhus, Denmark), H. Hoffmann (Aarhus, Denmark), J. Schmid (Aarhus, Denmark). Sputum eosinophilia is a useful biomarker for treatment failure of biologics for severe eosinophilic asthma. 880
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|